All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Wilms tumor suppressor gene 1 (WT1) is one of the most important TAAs classified by the National Cancer Institute. WT1, a zinc finger transcription factor, is highly expressed in many solid cancers and leukemia cells, but not in normal tissues (including hematopoietic progenitor and stem cells). Several studies have suggested that WT1 has an essential role in leukemogenesis and tumorigenesis, and it is required to maintain the transformed phenotype/function; therefore, tumor escape from immune surveillance as a result of downregulation of WT1 expression is unlikely to occur, marking WT1 as an attractive and important target for immunotherapy. The WT1Db126 (RMFPNAPYL) peptide was identified by screening the WT1 aa sequence for 9-mer peptides that include major anchormotifs for binding to HLA-A2. In vitro immunization elicits WT1 peptide-specific CTLs that mediate lysis of WT1-expressing tumor cells, indicating that this peptide constitutes a highly immunogenic epitope. HLA-A2-WT1Db126 complex is a target of TCR-like antibodies for anti-WT1Db126 peptide CAR-T cell development.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC266 | Anti-HLA-A2-WT1Db126 (F2) h(41BB-FcγR1γ) CAR, pCDCAR1 | Human | F2 | Human | scFv-CD28-FcγR1γ | Retroviral | T cell | ||
CAR-LC267 | Anti-HLA-A2-WT1Db126 (F3) h(41BB-FcγR1γ) CAR, pCDCAR1 | Human | F3 | Human | scFv-CD28-FcγR1γ | Retroviral | T cell | ||
CAR-MZ123 | Anti-HLA-A2/WT1Db126 (F2) h(CD28- FcγRIγ) CAR, pCDCAR1 | Human | F2 | Human | scFv-FcγRIγ | Retroviral | T cell | ||
CAR-MZ124 | Anti-HLA-A2/WT1Db126 (F3) h(CD28- FcγRIγ) CAR, pCDCAR1 | Human | F3 | Human | scFv-FcγRIγ | Retroviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION